Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: A matched cohort study

Blood

Volumn 126, Issue 4, 2015, Pages 494-499

  Donato, Jessica ^a   Campigotto, Federico ^b   Uhlmann, Erik J ^a   Coletti, Erika ^a   Neuberg, Donna ^b   Weber, Griffin M ^c   Zwicker, Jeffrey I ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Harvard Medical School Center for Biomedical Informatics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BRAIN HEMORRHAGE; BRAIN METASTASIS; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; KIDNEY CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM; BRAIN TUMOR; CANCER STAGING; CASE CONTROL STUDY; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; FOLLOW UP; INTRACRANIAL HEMORRHAGES; MIDDLE AGED; MORTALITY; NEOPLASMS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY; SURVIVAL RATE; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BOSTON; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; ENOXAPARIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84937009644     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-626788     Document Type: Article

References (21)

1. Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol. 2006;24(8):1310-1318.
2. Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. Neurooncol. 2015;17(4):488-504.
3. Sjöblom L, Hårdemark H-G, Lindgren A, et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke. 2001;32(11):2567-2574.
4. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet. 2009;373(9675):1632-1644.
5. Lee AY, Levine MN, Baker RI, et al Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.
6. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer. 1994;73(2):493-498.
7. Alvarado G, Noor R, Bassett R, et al. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res. 2012;22(4):310-315.
8. Srivastava G, Rana V, Wallace S, et al. Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients. J Thorac Oncol. 2009;4(3):333-337.
9. Licata B, Turazzi S. Bleeding cerebral neoplasms with symptomatic hematoma. J Neurosurg Sci. 2003;47(4):201-210, discussion 210.
10. Murphy SN, Weber G, Mendis M, et al. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2). J Am Med Inform Assoc. 2010;17(2):124-130.
11. Yang W, Feng Y, Zhang Y, Yan J, Fu Y, Chen S. Volume quantification of acute infratentorial hemorrhage with computed tomography: validation of the formula 1/2ABC and 2/3SH. PLoS ONE. 2013;8(4):e62286.
12. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993;24(7):987-993.
13. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. Accessed May 26, 2015.
14. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
15. Vitale FV, Rotondo S, Sessa E, et al. Low molecular weight heparin administration in cancer patients with hypercoagulability-related complications and carrying brain metastases: a case series study. J Oncol Pharm Pract. 2012;18(1):10-16.
16. Campigotto F, Neuberg D, Zwicker JI. Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier. J Thromb Haemost. 2012;10(7):1449-1451.
17. Kondziolka D, Bernstein M, Resch L, et al. Significance of hemorrhage into brain tumors: clinicopathological study. J Neurosurg. 1987;67(6):852-857.
18. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846-1850.
19. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458-464.
20. Noble S. Heparins and cancer survival: where do we stand? Thromb Res. 2014;133(Suppl 2):S133-S138.
21. Lyman GH, Khorana AA, Kuderer NM, et al American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189-2204.